Ann: Share Purchase Plan Offer Booklet, page-22

First 22 Last

Share
Profile

Follow
IndexInvestor

9,048 Posts.

1472

19/09/21

23:59

Post #: 56191742
Share

Originally posted by What A Gas: ↑

IMO, not necessarily.

If the 'placebo' does its job, then the playing field is levelled. Due to 'blindness', no one knows whether they are receiving the drug or not and even with or without drug efficacy most could perceive improvement and thus go on with the trial.

If the 'placebo' has little effect AND the drug is efficacious, then in this simplistic case 50% would drop out and 50% would continue.

The reality is much more complex than the two hand picked scenarios above and will only be revealed by analysis of the LAVENDER blinded trial data. However, the number of LILAC enrollments is perhaps not such a lay down misere indicator of drug efficacy as it may appear at face value. Anything under 50% enrollment would be a worrying sign, but above that .... who knows?

Expand

Please explain why anyone wouldn't continue to Lilac 1 and definitely get the drug.

When they make this decision, they don't know whether they had placebo or drug in Lavender.

The only meaningful number is the number continuing to Lilac 2 (whatever that is).

NEU Price at posting: $2.08 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

First 22 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.31		Change 0.770(6.14%)		Mkt cap ! $1.650B

Open	High	Low	Value	Volume
$12.96	$14.00	$12.91	$19.76M	1.453M

Buyers (Bids)

No.	Vol.	Price($)
1	3000	$13.30

Sellers (Offers)

Price($)	Vol.	No.
$13.33	3716	1

View Market Depth

No.	Vol.	Price($)
1	3000	13.300
2	10200	13.200
1	2500	13.190
2	1750	13.180
1	50	13.170

Price($)	Vol.	No.
13.330	3716	1
13.370	3716	1
13.390	600	1
13.400	3783	2
13.430	3716	1

Last trade - 16.10pm 26/06/2025 (20 minute delay)

NEU (ASX) Chart

Ann: Share Purchase Plan Offer Booklet, page-22

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Share Purchase Plan Offer Booklet, page-22

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

'Not possible' to port renewable gas: ACCC takes AGN to court

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News